Publikationen
J Exp Clin Cancer Res. 2019 Jul 8;38(1):292. doi: 10.1186/s13046-019-1286-9.
Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasiveness.
Richter C, Marquardt S, Li F, Spitschak A, Murr N, Edelhäuser BAH, Iliakis G, Pützer BM, Logotheti S.Theranostics. 2019 Feb 20;9(5):1490-1509. doi: 10.7150/thno.29546.
Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers.
Goody D, Gupta SK, Engelmann D, Spitschak A, Marquardt S, Mikkat S, Meier C, Hauser C, Gundlach JP, Egberts JH, Martin H, Schumacher T, Trauzold A, Wolkenhauer O, Logotheti S, Pützer BM.Theranostics 2018; 8(4):1106-1120.
MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance.
Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, Wolkenhauer O, Pützer BM, Vera J.Semin Cancer Biol. 2018 Jun 29. pii: S1044-579X(18)30018-X. doi: 10.1016/j.
